# Codex Review: medical_monitoring_daily_diff_summary_20260803

Date: 2026-08-03
Delegated-agent output: not dispatched; direct Codex implementation. The runner report path remains unused.

## Verdict

**accepted_for_offline_code_scope**

## Boundary Check

- No Hermes worker was dispatched; this was a direct Codex implementation. Changes are limited to the workbench frontend feature, its existing daily-run panel seam, derived `frontend/dist` output from the build, and this task's context/review/metrics/active-slice records.
- No backend/API, risk/disposition, runtime store, B6/C14, source-token/CAS, medical-writing, service, browser, provider or real-project file was changed.
- The normalizer consumes only explicit `detail.diff` fields and never fills missing evidence with zero.

## Codex Verification

- Focused `medicalMonitoringDailyDiffView` model: **27 assertions passed**.
- `node --test frontend/src/features/medical-monitoring/*.test.mjs`: **26/26 files passed**.
- `frontend`: `npm run build` passed; **1936 modules transformed**. Existing >500 kB chunk advisory remains.
- Port check: 8911, 5174, 8910 and 4173 were empty.
- Static review confirms the UI distinguishes new/changed/persisting/removed rows, re-review rows, field/schema changes, identity matches, removal-eligible versus removal-blocked evidence, and explicit full-snapshot declaration.
- Browser/runtime and real-project checks were intentionally not run because the current release dossier and B6/C14 gates remain blocked.

## Delegated-Agent Output Review

- No delegated output to review. Direct Codex kept the change in the existing read-only consumer seam and preserved the state-machine/action controls.
- No clinical, causal, completeness, or release-readiness claim is introduced. Malformed or missing arrays, count maps, booleans and SHA-256 evidence remain visibly partial.

## Residual Risk

The summary has not been exercised against a live frozen batch, browser viewport, or real project data. It does not prove diff algorithm correctness, source completeness, clinical interpretation, persistence/restart, B6/C14 activation, or commercial release readiness.
